The Experts below are selected from a list of 398361 Experts worldwide ranked by ideXlab platform
M D Kazatchkine - One of the best experts on this subject based on the ideXlab platform.
-
anti idiotypes against anti neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific igg for Therapeutic Use and in the remission sera of patients with systemic vasculitis
Clinical and Experimental Immunology, 2008Co-Authors: F Rossi, C M Lockwood, D R W Jayne, M D KazatchkineAbstract:Anti-neutrophil cytoplasmic antigen (ANCA) activity was inhibited in 15 out of 21 sera from patients with acute systemic vasculitis following incubation with normal polyspecific IgG for Therapeutic Use (IVIg). ANCA antibodies reacted with IVIg through idiotypic-anti-idiotypic interactions, as shown in competitive binding assays using F(ab')2 fragments from IVIg and affinity chromatography of ANCA IgG on Sepharose-bound F(ab')2 fragments from IVIg. Co-incubation of sera from patients with acute systemic vasculitis with paired autologous remission stage sera also resulted in inhibition of ANCA activity in acute sera. Remission sera contain IgM and IgG capable of interacting with beta and or alpha idiotypes of ANCA IgG from acute sera. Anti-idiotypic IgM may account for the lack of expression of ANCA activity in whole serum from patients in remission from systemic vasculitis, which were found to contain high titres of ANCA IgG. These observations suggest that remission of systemic vasculitis is associated with the generation of anti-idiotypes against autoantibodies rather than the suppression of production of ANCA autoantibodies. IVIg may modulate the activity of systemic vasculitis in vivo.
Massimo Volpe - One of the best experts on this subject based on the ideXlab platform.
-
natriuretic peptides an update on bioactivity potential Therapeutic Use and implication in cardiovascular diseases
American Journal of Hypertension, 2008Co-Authors: Speranza Rubattu, Sebastiano Sciarretta, Valentina Valenti, Rosita Stanzione, Massimo VolpeAbstract:The natriuretic peptide system includes three known peptides: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). They contribute to the regulation of cardiovascular homeostasis through diuretic, natriuretic, and vasodilatory properties. Among them, ANP has received particular attention becaUse of its effects on blood pressure regulation and cardiac function. Although the potential for its Therapeutic application in the treatment of hypertension and heart failure has been evaluated in several experimental and clinical investigations, no pharmacological approach directly targeted at modulation of ANP levels has ever reached the stage of being incorporated into clinical practice. Recently, ANP has also received attention as being a possible cardiovascular risk factor, particularly in the context of hypertension, stroke, obesity, and metabolic syndrome. Abnormalities in either peptide levels or peptide structure are thought to underlie its implied role in mediating cardiovascular diseases. Meanwhile, BNP has emerged as a relevant marker of left ventricular (LV) dysfunction and as a Useful predictor of future outcome in patients with heart failure. This review deals with the major relevant findings related to the cardiovascular and metabolic effects of natriuretic peptides, to their potential Therapeutic Use, and to their role in mediating cardiovascular diseases.
Alexander Enk - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic Use of anti ctla 4 antibodies
International Immunology, 2015Co-Authors: Christian U. Blank, Alexander EnkAbstract:Targeting CTLA-4 represents a new type of immunoTherapeutic approach, namely immune checkpoint inhibition. Blockade of CTLA-4 by ipilimumab was the first strategy to achieve a significant clinical benefit for late-stage melanoma patients in two phase 3 trials. These results fueled the notion of immunotherapy being the breakthrough strategy for oncology in 2013. Subsequently, many trials have been set up to test various immune checkpoint modulators in malignancies, not only in melanoma. In this review, recent new ideas about the mechanism of action of CTLA-4 blockade, its current and future Therapeutic Use, and the intensive search for biomarkers for response will be discussed. Immune checkpoint blockade, targeting CTLA-4 and/or PD-1/PD-L1, is currently the most promising systemic Therapeutic approach to achieve long-lasting responses or even cure in many types of cancer, not just in patients with melanoma.
T Nakashima - One of the best experts on this subject based on the ideXlab platform.
-
high yield preparation of recombinant human α thrombin for Therapeutic Use
Journal of Bioscience and Bioengineering, 2015Co-Authors: Akihiro Meta, Masaki Hirashima, Takayuki Imamura, Ryoichi Kawamura, Kentaro Yano, Kenji Uehara, T NakashimaAbstract:In this study, we established stable cell lines producing 1.5 mg/mL recombinant human prothrombin in 400-L fed-batch culture, using CHO DG44 cells as a host cell line. And we also established a recombinant human α-thrombin purification process that produces a purified product suitable for Use as a biopharmaceutical, by using recombinant ecarin from CHO DG44 cells, achieving a total yield of approximately 27% of prothrombin in culture medium. The establishment of stable cell lines with high expression levels, long-term passage stability and satisfactory scale-up are essential to ensure the stable supply of biopharmaceuticals. Furthermore, biopharmaceuticals must be of high quality to assure safety and effectiveness in target applications. We had previously reported that recombinant human prethrombin-2 expression level in a stable cell line established using the moUse myeloma cells, Sp2/0-Ag14, reached 200 μg/mL using animal-free materials in 50-L fed-batch culture. However, the productivity was insufficient to completely replace α-thrombin in human plasma preparations. By employing CHO DG44 cells as a host cell line, we had established a stable cell line and achieved significant improvements in quality, productivity of recombinant human α-thrombin manufacture suitable for Use as a biopharmaceutical.
Daniel Greve - One of the best experts on this subject based on the ideXlab platform.
-
the potential Therapeutic Use of phosphodiesterase 10 inhibitors
Expert Opinion on Therapeutic Patents, 2007Co-Authors: Jan Kehler, Andreas Ritzen, Daniel GreveAbstract:The discovery of the enzyme phosphodiesterase 10A (PDE10A) was reported simultaneously in 1999 by three independent groups. PDE10A has been shown by localisation studies to have the most restricted distribution of all the 11 known PDE families, with the PDE10A mRNA highly expressed only in the brain and testes. In the brain, mRNA and protein are highly enriched in the striatum and, together with increased pharmacological characterisation, this unique distribution of PDE10A in the brain indicates a potential Use of PDE10A inhibitors for treating neurological and psychiatric disorders, in particular, psychotic disorders like schizophrenia. However, PDE10A inhibitors have also been claimed to be Useful as treatment for cancer, diabetes and especially obesity. Two years after the reported discovery of PDE10A, Bayer filed the first patent application claiming PDE10A inhibitors, followed shortly thereafter by Pfizer. Since then, a number of scientific publications and filed patents testify to an increasing phar...
